Twelve-Month Outcomes of Standalone Travoprost Intracameral Implant in Glaucoma or Ocular Hypertension
= 0.085). Postoperatively, one case each of transient corneal edema and retinal edema were observed, which self-resolved without sequelae. Thus, standalone travoprost implant administration significantly reduced IOP over 12 months in OAG and OHT, while maintaining a low medication burden. Similar IOP reductions were observed regardless of prior SLT treatment and glaucoma severity.
Authors
- Savak Teymoorian (ORCID: https://orcid.org/0000-0003-0906-197X)
- Dana M. Hornbeak
- Erik Barr
- Jasmin Kaur
Institutions
- Harvard Eye Associates (US)
- Soka University of America (US)
Publication Details
- Journal
- Life
- Published
- 2026-04-07
- DOI
- https://doi.org/10.3390/life16040614
- Primary Topic
- Glaucoma and retinal disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00